Clinical Trial Update: Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating pharmacokinetics, activity, and safety of ruxolitinib in pediatric patients with Grade II-IV acute graft-versus-host disease; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Graft Versus Host Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-11-08